A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 microg B.I.D. USING AEROCHAMBER PLUS SPACING DEVICE AND BECLOMETHASONE DIPROPIONATE HFA pMDI 200 microg B.I.D. USING THE VOLUMATIC SPACING DEVICE IN CHILDREN WITH MILD ASTHMA DURING A 2-WEEK TREATMENT PERIOD

Trial Profile

A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 microg B.I.D. USING AEROCHAMBER PLUS SPACING DEVICE AND BECLOMETHASONE DIPROPIONATE HFA pMDI 200 microg B.I.D. USING THE VOLUMATIC SPACING DEVICE IN CHILDREN WITH MILD ASTHMA DURING A 2-WEEK TREATMENT PERIOD

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 07 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 19 May 2009 Results presented at 105th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top